Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Chemicals — Specialty & Commodity.”
₹1,134 Cr revenue.
COGS 51.3%, employees 10.2%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 14.1%▲ | 7.6% |
| ROCE | 18.0%▲ | 10.9% |
| Net Margin | 11.5%▲ | 5.1% |
| EBITDA Margin | 17.3%▲ | 12.1% |
| Debt To Equity | 0.01x▼ | 0.20x |
| Rev Growth 3yr | 14.7%▲ | 5.9% |
| EPS Growth 3yr | 25.9%▲ | -9.4% |
Historical valuation data not available.
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,175 Cr +3.7% | ₹1,134 Cr +6.1% | ₹1,069 Cr +8.9% | ₹982 Cr +27.8% | ₹768 Cr +26.8% | ₹606 Cr -2.2% | ₹619 Cr +3.0% | ₹601 Cr |
| Other Income | ₹48 Cr +4.0% | ₹46 Cr +49.5% | ₹31 Cr +62.9% | ₹19 Cr +37.7% | ₹14 Cr -6.3% | ₹15 Cr +24.2% | ₹12 Cr +2.7% | ₹12 Cr |
| Total Income | ₹1,223 Cr +3.7% | ₹1,180 Cr +7.3% | ₹1,100 Cr +9.9% | ₹1,001 Cr +28.0% | ₹782 Cr +26.0% | ₹621 Cr -1.7% | ₹631 Cr +3.0% | ₹613 Cr |
| COGS | ₹597 Cr +2.7% | ₹581 Cr +4.4% | ₹557 Cr +0.1% | ₹556 Cr +28.8% | ₹431 Cr +37.2% | ₹314 Cr +0.3% | ₹314 Cr -2.0% | ₹320 Cr |
| ₹1,038 Cr +7.0% | ₹970 Cr +7.4% | ₹904 Cr +6.5% | ₹848 Cr +25.1% | ₹678 Cr +28.8% | ₹526 Cr -3.3% | ₹544 Cr +6.3% | ₹512 Cr | |
| Profit Before Tax | ₹185 Cr -11.7% | ₹210 Cr +6.8% | ₹196 Cr +29.1% | ₹152 Cr +42.4% | ₹107 Cr +13.2% | ₹94 Cr -1.2% | ₹95 Cr +1.4% | ₹94 Cr |
| ₹45 Cr -14.6% | ₹52 Cr +4.9% | ₹50 Cr +28.0% | ₹39 Cr +39.1% | ₹28 Cr +10.3% | ₹25 Cr +29.9% | ₹20 Cr -35.3% | ₹30 Cr | |
| Net Profit | ₹140 Cr -10.8% | ₹157 Cr +7.5% | ₹146 Cr +29.5% | ₹113 Cr +43.4% | ₹79 Cr +14.4% | ₹69 Cr -9.3% | ₹76 Cr +18.7% | ₹64 Cr |
| Profit (Owners) | ₹140 Cr -10.8% | ₹157 Cr +7.5% | ₹146 Cr +29.5% | ₹113 Cr +43.4% | ₹79 Cr +14.4% | ₹69 Cr -9.3% | ₹76 Cr +18.7% | ₹64 Cr |
| Other Comprehensive Income | (₹2 Cr) -373.3% | (₹0.45 Cr) +81.4% | (₹2 Cr) -61.3% | (₹2 Cr) ↓ Decline | ₹1 Cr ↑ Recovery | (₹0.70 Cr) +36.4% | (₹1 Cr) | (₹0.04 Cr) |
| EPS | ₹3.09 | ₹3.47 | ₹3.23 | ₹2.49 | ₹1.74 | ₹1.52 | ₹1.67 | ₹1.41 |
| Diluted Shares | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr | ₹45 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
No earnings call transcripts available.
Update on Press Release of CARE Rating Limited
Newspaper Publication of dispatch of Postal Ballot Notice.
Newspaper publication of Unaudited Financial Result of the Company for quarter ended 31st December, 2025
Trading Window shall closed from 1st January, 2026 until 48 hours after the financial result of the company for quarter ended 31st December, 2025 have been disseminated to the Stock Exchange.
Newspaper Publication of Unaudited Financial Result of Company for Quarter and Half Year ended 30th September, 2025
Unaudited Quarterly Financial Result along with Limited review report for Quarter ended September 30, 2025
Outcome of Board Meeting held on 06th November, 2025
Grauer & Weil India Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve Unaudited Financial Result .... Graue...
Certificate under reg. 74(5) SEBI (DP) Regulation, 2018 for quarter ended 30th September, 2025
Trading Window shall close from 1st October, 2025 until 48 hours after the financial result of the company for quarter ended 30th September, 2025 have been disseminated to the stock exchange.
BSE Ltd. rejected Reclassification Application of M/s. Waluj Beverages LLP filed under regulation 31A of SEBI Listing Regulation.
M/s Grauer & Weil (Sanghai) Limited, wholly owned subsidiary of the Company have applied for striking off.
Scrutinizer Report for evoting at AGM 2025
Scrutinizer Report for evoting at AGM
Newspaper publication of Unaudited standalone and consolidated Quarterly Financial Results of the Company for the Quarter ended 30-06-2025.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.